<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259853</url>
  </required_header>
  <id_info>
    <org_study_id>the QFR-STEMI study</org_study_id>
    <nct_id>NCT04259853</nct_id>
  </id_info>
  <brief_title>Quantitative Fractional Ratio-guided Revascularization in STEMI Patients With Multi-vessel Disease</brief_title>
  <official_title>Quantitative Fractional Ratio-guided Non-culprit-vessel Revascularization in STEMI Patients With Multi-vessel Disease: a Prospective Multi-center Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pulse Medical Imaging Technology (Shanghai) Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      About half of patients with ST-segment elevation myocardial infarction (STEMI) have
      multi-vessel lesions (&gt; 50% diameter stenosis). But how to deal with the non-culprit vessels
      is still controversial. Previous studies have shown that flow fractional reserve (FFR)-guided
      revascularization on non-culprit vessels can further improve prognosis of such patients.
      However, FFR requires the use of pressure guidewire and special drugs such as adenosine to
      maximize induction of hyperemia forcoronary artery, which will increase the cost of operation
      and may cause additional risks. Quantitative flow ratio (QFR) is a novel angiography-based
      method for deriving FFR without pressure wire or induction of hyperemia. In present, there
      still are poor data about QFR-guided revascularization on non-culprit vessels in patients
      with STEMI. The purpose of this study is to compare the clinical effects of QFR-guided with
      angiography-guided revascularization on non-culprit vessel in STEMI patients with
      multi-vessel lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      41% -67% of patients with acute ST-segment elevation myocardial infarction (STEMI) have
      severe stenosis in non-culprit vessels (&gt; 50% diameter stenosis). Compared with patients with
      single-vessel lesion, these patients with multi-vessel disease have a worse survival rate
      after percutaneous coronary intervention (PCI). Previous studies have shown that they not
      only receive more revascularization than the latter but also have a higher incidence of heart
      failure and more frequent electrical instability after myocardial infarction.

      Early guidelines from European Society of Cardiology and the American College of
      Cardiology/American Heart Association discourage treating the non-culprit vessels in the
      acute phase. However, these recommendations are given mainly based on some small-sample
      retrospective studies.

      With the use of second-generation drug-eluting stents and novel antithrombotic drugs, the
      clinical benefits from primary PCI and elective PCI have been greatly improved. Results from
      some small-sample prospective randomized studies have demonstrated that complete
      revascularization on STEMI patients with multi-vessel diseases is superior to a strategy of
      culprit-only revascularization. Especially, more recent two trials (PRAMI and CVLPRIT)
      further confirmed that complete revascularization in the acute phase can produce beneficial
      clinical results compared to culprit-only revascularization. However, stenting for these
      lesions in the two studies was decided based on angiographic findings regardless of whether
      the lesion caused myocardial ischemia or symptoms. Moreover, coronary angiography may
      underestimate and overestimate the functional severity of the lesion. Stent implantation
      preventively will lead to overtreatment, increasing additional cost and risk. Finally, not
      all such studies demonstrated positive findings. For example, the PRAGUE-13 study comparing
      angiography-guided complete revascularization with culprit-only treatment did not find that
      complete revascularization has more advantages. Therefore, the angiography-guided strategy
      for complete revascularization in STEMI patients with multi-vessel lesions remains
      questionable.

      The clinical value of flow fractional reserve (FFR) as a gold standard for the assessment of
      coronary function in ischemia has been well confirmed in coronary intervention. Recently,
      three studies based on coronary functioning have shown that FFR-guided complete
      revascularization is superior to the strategy of only treating culprit lesion. However,
      clinical benefit of FFR is mainly from reducing the incidence of subsequent revascularization
      but not hard endpoints such as death. On the other hand, the time of treatment for
      non-culprit vessel was not completely consistent and not all patients in the FFR group
      received FFR measurements in these studies. Heterogeneities from these studies may weaken the
      clinical benefit of FFR in guiding complete revascularization in STEMI patients. Although the
      current guidelines recommend that non-culprit lesions be allowed for treatment when emergency
      PCI is performed on specific patients (Class IIa, Level A), it is still necessary to conduct
      studies targeted on these issues to further clarify the value of coronary functional approach
      in revascularization on non-culprit vessel of patients with STEMI. FFR also has certain
      limitations: first, FFR is an invasive test, which requires a pressure guide wire, in turn
      inevitably increases the cost of operation and may cause additional procedure-associated
      risks; secondly, drugs such as adenosine are required to maximize hyperemia of coronary
      artery, and these adverse drug reactions may increase the incidence of adverse clinical
      events, especially in the acute state of myocardial infarction.

      Quantitative flow ratio (QFR) is a novel angiography-based method accurate assessing coronary
      physiological functions for deriving FFR without the use of pressure wire and induction of
      hyperemia. The three-dimensional reconstruction of the coronary arteries is performed through
      two angiographic images with an acquisition angle difference of &gt; 25 Â°. The QFR value is
      finally calculated based on the flow velocity obtained by a method of frame rate counting. In
      the past five years, a vast number of studies confirmed QFR is highly consistent with FFR in
      the diagnosis of myocardial ischemia, and the diagnostic accuracy of QFR is significantly
      higher than that of quantitative coronary angiography. Recent studies have also shown that,
      compared with conventional angiography-guided PCI, QFR-guided PCI for patients with stable
      angina pectoris has significantly reduced adverse cardiovascular events such as death and
      revascularization. Especially, QFR and FFR can accurately assess the coronary physiological
      function status of non-culprit lesions in emergency PCI patients, and its effectiveness is
      consistent with FFR applied to patients with stable coronary heart disease. Although previous
      studies provided the theoretical support, there are still poor data on QFR-guided non-culprit
      revascularization on STEMI patients with multi-vessel disease. Thus, we hypothesized that
      strategies for QFR to assess all blood flow limiting lesions and guide revascularization
      during emergency PCI would lead to better short-term and long-term clinical outcomes for
      STEMI patients with multiple vessel lesions, including improved left ventricular function,
      less secondary revascularization, less frequency of hospitalization, lower medical costs.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 24, 2020</start_date>
  <completion_date type="Anticipated">February 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 24, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>12 months</time_frame>
    <description>A composite endpoint of all-cause mortality, recurrent myocardial infarction, ischemia driven revascularization, and hospitalization for heart failure at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year MACE</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of all-cause mortality, recurrent myocardial infarction, ischemia driven revascularization, and hospitalization for heart failure at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year MACE</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence of all-cause mortality, recurrent myocardial infarction, ischemia driven revascularization, and hospitalization for heart failure at 36 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>up to 36 months</time_frame>
    <description>The incidence of stent thrombosis at 12, 24, 36 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding</measure>
    <time_frame>up to 36 months</time_frame>
    <description>The incidence of bleeding at 12, 24, 36 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke</measure>
    <time_frame>up to 36 months</time_frame>
    <description>The incidence of stroke at 12, 24, 36 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Restenosis</measure>
    <time_frame>12 months</time_frame>
    <description>The incidence of restenosis at 12 months.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">638</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>Multi-Vessel Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>QFR-guided PCI group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QFR-guided revascularization on non-culprit vessels in patients with STEMI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAG-guided PCI group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CAG-guided revascularization on non-culprit vessels in patients with STEMI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI</intervention_name>
    <description>Revascularization on non culprit vessel</description>
    <arm_group_label>CAG-guided PCI group</arm_group_label>
    <arm_group_label>QFR-guided PCI group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suitable for emergency PCI within 12 hours;

          -  At least one lesion with a stenosis of 50% - 90% in the non culprit vessel and PCI
             required by the operator.

          -  Voluntary acceptance of all follow-up assessments required by the protocol.

          -  The subject (or legal guardian) who understands the protocol requirements and
             treatment procedures, and signs a written informed consent before performing the
             examination or operation specified in the scheme.

        Exclusion Criteria:

          -  Left main lesion (a stenosis of â¥ 50%).

          -  STEMI caused by stent thrombosis.

          -  Non culprit vessels are chronic occlusive disease (CTO).

          -  The anatomy of non culprit vessels not suitable for PCI.

          -  The TIMI flow of non culprit vessels less than grade 2.

          -  Patients with one of the following conditions in the treatment of infarct related
             vessel:

               1. Coronary artery perforation.

               2. After the treatment, there is permanent no reflow (TIMI 0-1).

               3. The stent could not be implanted.

          -  Patients with Killip grade III-IV who can still not tolerate PCI again after treated
             for one week.

          -  Known severe cardiac valve dysfunction requiring surgery during follow-up.

          -  Subjects could not tolerate dual-antiplatelet therapy.

          -  Woman with pregnancy or planning to pregnancy.

          -  Patients with known allergy to the study stent system (sirolimus, everolimus,
             zotarolimus) or to protocol-required concomitant medications

          -  Patients participating any other clinical trials.

          -  Expected the patients who can not be followed up regularly according to the protocol
             or lost during the follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lianglong Chen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujian Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuqing Hospital</name>
      <address>
        <city>Fuqing</city>
        <state>Fujian</state>
        <zip>350300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Longyan City</name>
      <address>
        <city>Longyan</city>
        <state>Fujian</state>
        <zip>364000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Putian City</name>
      <address>
        <city>Putian</city>
        <state>Fujian</state>
        <zip>351100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <zip>362000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QUANZHOU First Hospital</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <zip>362002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanming First Hospital</name>
      <address>
        <city>Sanming</city>
        <state>Fujian</state>
        <zip>365000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhangzhou city's Hospital</name>
      <address>
        <city>Zhangzhou</city>
        <state>Fujian</state>
        <zip>363000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Corpus RA, House JA, Marso SP, Grantham JA, Huber KC Jr, Laster SB, Johnson WL, Daniels WC, Barth CW, Giorgi LV, Rutherford BD. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. Am Heart J. 2004 Sep;148(3):493-500.</citation>
    <PMID>15389238</PMID>
  </reference>
  <reference>
    <citation>Hanratty CG, Koyama Y, Rasmussen HH, Nelson GI, Hansen PS, Ward MR. Exaggeration of nonculprit stenosis severity during acute myocardial infarction: implications for immediate multivessel revascularization. J Am Coll Cardiol. 2002 Sep 4;40(5):911-6.</citation>
    <PMID>12225715</PMID>
  </reference>
  <reference>
    <citation>Janardhanan R, Kenchaiah S, Velazquez EJ, Park Y, McMurray JJ, Weaver WD, Finn PV, White HD, Marin-Neto JA, O'Connor C, Pfeffer MA, Califf RM, Solomon SD; VALIANT Investigators. Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. Am Heart J. 2006 Jul;152(1):183-9.</citation>
    <PMID>16824854</PMID>
  </reference>
  <reference>
    <citation>Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011 Dec 6;124(23):e574-651. doi: 10.1161/CIR.0b013e31823ba622. Epub 2011 Nov 7. Erratum in: Circulation. 2012 Feb 28;125(8):e412. Dosage error in article text.</citation>
    <PMID>22064601</PMID>
  </reference>
  <reference>
    <citation>Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010 Jan 16;375(9710):201-9. doi: 10.1016/S0140-6736(09)62127-9. Epub 2010 Jan 7.</citation>
    <PMID>20060578</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010 May 6;362(18):1663-74. doi: 10.1056/NEJMoa0910496.</citation>
    <PMID>20445180</PMID>
  </reference>
  <reference>
    <citation>Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009 Feb 28;373(9665):723-31. doi: 10.1016/S0140-6736(09)60441-4.</citation>
    <PMID>19249633</PMID>
  </reference>
  <reference>
    <citation>Khattab AA, Abdel-Wahab M, RÃ¶ther C, Liska B, Toelg R, Kassner G, Geist V, Richardt G. Multi-vessel stenting during primary percutaneous coronary intervention for acute myocardial infarction. A single-center experience. Clin Res Cardiol. 2008 Jan;97(1):32-8. Epub 2007 Aug 17.</citation>
    <PMID>17694377</PMID>
  </reference>
  <reference>
    <citation>Hassan A, ElGuindy A, Antoniucci D. Culprit lesion-only versus complete revascularization in patients with STEMI: Lessons learned from PRAMI, CvLPRIT, and DANAMI-3 PRIMULTI. Glob Cardiol Sci Pract. 2015 Dec 22;2015(5):60. doi: 10.5339/gcsp.2015.60. eCollection 2015.</citation>
    <PMID>26925405</PMID>
  </reference>
  <reference>
    <citation>Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C, Oldroyd KG; PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013 Sep 19;369(12):1115-23. doi: 10.1056/NEJMoa1305520. Epub 2013 Sep 1.</citation>
    <PMID>23991625</PMID>
  </reference>
  <reference>
    <citation>Kelly DJ, McCann GP, Blackman D, Curzen NP, Dalby M, Greenwood JP, Fairbrother K, Shipley L, Kelion A, Heatherington S, Khan JN, Nazir S, Alahmar A, Flather M, Swanton H, Schofield P, Gunning M, Hall R, Gershlick AH. Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design. EuroIntervention. 2013 Feb 22;8(10):1190-8. doi: 10.4244/EIJV8I10A183.</citation>
    <PMID>23425543</PMID>
  </reference>
  <reference>
    <citation>Hlinomaz O, Groch L, PolokovÃ¡ K, et al. Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE-13 trial. Kardiol Rev Int Med 2015;17:214-220.</citation>
  </reference>
  <reference>
    <citation>EngstrÃ¸m T, KelbÃ¦k H, Helqvist S, HÃ¸fsten DE, KlÃ¸vgaard L, Holmvang L, JÃ¸rgensen E, Pedersen F, SaunamÃ¤ki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, AarÃ¸e J, Jensen SE, Raungaard B, KÃ¸ber L; DANAMI-3âPRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3âPRIMULTI): an open-label, randomised controlled trial. Lancet. 2015 Aug 15;386(9994):665-71.</citation>
    <PMID>26347918</PMID>
  </reference>
  <reference>
    <citation>Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh CE, Piroth Z, Horak D, Wlodarczak A, Ong PJ, Hambrecht R, AngerÃ¥s O, Richardt G, Omerovic E; Compare-Acute Investigators. Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. N Engl J Med. 2017 Mar 30;376(13):1234-1244. doi: 10.1056/NEJMoa1701067. Epub 2017 Mar 18.</citation>
    <PMID>28317428</PMID>
  </reference>
  <reference>
    <citation>Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, Meeks B, Di Pasquale G, LÃ³pez-SendÃ³n J, Faxon DP, Mauri L, Rao SV, Feldman L, Steg PG, Avezum Ã, Sheth T, Pinilla-Echeverri N, Moreno R, Campo G, Wrigley B, Kedev S, Sutton A, Oliver R, RodÃ©s-Cabau J, StankoviÄ G, Welsh R, Lavi S, Cantor WJ, Wang J, Nakamya J, Bangdiwala SI, Cairns JA; COMPLETE Trial Steering Committee and Investigators. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2019 Oct 10;381(15):1411-1421. doi: 10.1056/NEJMoa1907775. Epub 2019 Sep 1.</citation>
    <PMID>31475795</PMID>
  </reference>
  <reference>
    <citation>Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, JÃ¼ni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A; European Society of Cardiology Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol Ã, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; EACTS Clinical Guidelines Committee, Sousa Uva M, Achenbach S, Pepper J, Anyanwu A, Badimon L, Bauersachs J, Baumbach A, Beygui F, Bonaros N, De Carlo M, Deaton C, Dobrev D, Dunning J, Eeckhout E, Gielen S, Hasdai D, Kirchhof P, Luckraz H, Mahrholdt H, Montalescot G, Paparella D, Rastan AJ, Sanmartin M, Sergeant P, Silber S, Tamargo J, ten Berg J, Thiele H, van Geuns RJ, Wagner HO, Wassmann S, Wendler O, Zamorano JL; Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery; European Association of Percutaneous Cardiovascular Interventions. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014 Oct;46(4):517-92. doi: 10.1093/ejcts/ezu366. Epub 2014 Aug 29.</citation>
    <PMID>25173601</PMID>
  </reference>
  <reference>
    <citation>Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Ting HH, O'Gara PT, Kushner FG, Ascheim DD, Brindis RG, Casey DE Jr, Chung MK, de Lemos JA, Diercks DB, Fang JC, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. J Am Coll Cardiol. 2016 Mar 15;67(10):1235-1250. doi: 10.1016/j.jacc.2015.10.005. Epub 2015 Oct 21. Review. Erratum in: J Am Coll Cardiol. 2016 Mar 29;67(12):1506.</citation>
    <PMID>26498666</PMID>
  </reference>
  <reference>
    <citation>Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, Lansky A, Barbato E, van der Heijden LC, Reiber JH, Holm NR, Wijns W; FAVOR Pilot Trial Study Group. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. JACC Cardiovasc Interv. 2016 Oct 10;9(19):2024-2035. doi: 10.1016/j.jcin.2016.07.013.</citation>
    <PMID>27712739</PMID>
  </reference>
  <reference>
    <citation>Xu B, Tu S, Qiao S, Qu X, Chen Y, Yang J, Guo L, Sun Z, Li Z, Tian F, Fang W, Chen J, Li W, Guan C, Holm NR, Wijns W, Hu S. Diagnostic Accuracy of Angiography-Based Quantitative Flow Ratio Measurements for Online Assessment of Coronary Stenosis. J Am Coll Cardiol. 2017 Dec 26;70(25):3077-3087. doi: 10.1016/j.jacc.2017.10.035. Epub 2017 Oct 31.</citation>
    <PMID>29101020</PMID>
  </reference>
  <reference>
    <citation>Lauri FM, Macaya F, MejÃ­a-RenterÃ­a H, Goto S, Yeoh J, Nakayama M, QuirÃ³s A, Liontou C, Pareek N, FernÃ¡ndez-OrtÃ­z A, Macaya C, MacCarthy P, Escaned J; Collaborators. Angiography-derived functional assessment of non-culprit coronary stenoses in primary percutaneous coronary intervention. EuroIntervention. 2020 Apr 3;15(18):e1594-e1601. doi: 10.4244/EIJ-D-18-01165.</citation>
    <PMID>31543501</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Lianglong Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ST Elevation Myocardial Infarction</keyword>
  <keyword>Multi-Vessel Coronary Artery Stenosis</keyword>
  <keyword>Coronary physiological function</keyword>
  <keyword>Quantitative fractional ratio</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Multiple Chronic Conditions</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

